Xeris Biopharma Holdings (XERS) Cash from Financing Activities (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported Cash from Financing Activities for 7 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Financing Activities rose 106.26% year-over-year to $1.9 million; the trailing twelve-month figure through Jun 2026 stood at $6.7 million (up 455.85% YoY), and the FY2025 full-year result was $11.4 million, down 68.51% from the prior year.
• Cash from Financing Activities climbed to $1.9 million in Q2 2026 per XERS's latest filing, from -$8.8 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $78.2 million in Q1 2022 and bottomed at -$8.8 million in Q1 2026.
• Historically, Cash from Financing Activities has averaged $9.3 million across 5 years, with a median of $354000.0 in 2022.
• The widest YoY moves for Cash from Financing Activities: up 39224.8% in 2022, down 18800.0% in 2022.
• Over 5 years, Cash from Financing Activities stood at $49.2 million in 2022, then plunged by 102.51% to -$1.2 million in 2023, then surged by 132.25% to $398000.0 in 2024, then sank by 166.83% to -$266000.0 in 2025, then jumped by 830.45% to $1.9 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $1.9 million, -$8.8 million, and -$266000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.